

ALKEM LABORATORIES LTD.

Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955

Email: contact@alkem.com
 Website: www.alkemlabs.com

CIN: L00305MH1973PLC174201

30th December, 2023

The Corporate Relationship
Department

National Stock Exchange of India
Limited

BSE Limited Exchange Plaza,

Phiroze Jeejeebhoy Towers, Bandra Kurla Complex,

Dalal Street,
Mumbai 400 001.
Bandra East,
Mumbai 400 051.

Scrip Code: 539523 Scrip Symbol: ALKEM

Dear Sirs,

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("SEBI Listing Regulations")

This is to inform you that as part of the Company's operational strategy, the operations of the Company carried out at the St. Louis manufacturing facility situated in USA owned by M/s S&B Pharma LLC, a step-down subsidiary of the Company, ("Facility") are closed. Accordingly, all rights, title and interest in the land, improvements and personal property with respect to the said Facility owned by M/s S&B Pharma LLC, a step-down subsidiary of the Company in USA ("Seller") are sold to M/s New Mill Capital Holdings LLC ("Buyer") pursuant to the 'Purchase and Sale Agreement' executed between the Buyer and Seller.

The details as required under SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are enclosed herewith as Annexure I.

Kindly take the same on records.

Sincerely, For Alkem Laboratories Limited

Basudeo N Singh Executive Chairman DIN: 00760310

Encl: a/a



ALKEM LABORATORIES LTD.

Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955

• Email: contact@alkem.com • Website: www.alkemlabs.com

CIN: L00305MH1973PLC174201

Annexure I

Details under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Manufacturing unit proposed to be sold	St. Louis manufacturing facility of the Company situated at 1733, Gilsinn Lane, Fenton, Missouri 63026, USA.
The amount and percentage of the turnover or revenue or income and net worth	Amount of turnover: USD 3,850,600 (INR: 309,208,571)
contributed by such unit or division or undertaking or	% of Total Turnover: 0.27% on consolidated basis
subsidiary or associate company of the listed entity during the last financial year	Networth: USD 2,7361,366.32 (St. Louis, USA is a unit of S&B Pharma LLC, a step-down subsidiary of the Company in USA and hence we have mentioned the Networth of S&B Pharma LLC)
Date on which the agreement for sale has been entered into	The Purchase and Sale Agreement was entered into for sale of the Facility subject to satisfactory due diligence. The agreement was executed subject to completion of the above-mentioned condition on 15 th November, 2023.
The expected date of completion of sale	30 th December, 2023
Consideration received from such sale	USD 7,960,000.00
Brief details of buyers and whether any of the buyers belong to the promoter/	M/s New Mill Capital Holdings LLC, a Delaware Limited Liability Company (" Buyer ").
promoter group/ group companies. If yes, details thereof;	The Buyer does not belong to the promoter/ promoter group of the Company.
Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	The said transaction does not fall within the purview of related party transactions.



ALKEM LABORATORIES LTD.

Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955

• Email: contact@alkem.com • Website: www.alkemlabs.com

CIN: L00305MH1973PLC174201

Whether the sale, lease or	Not applicable
disposal of the undertaking is	
outside Scheme of	
Arrangement? If yes, details of	
the same including compliance	
with regulation 37A of LODR	
Regulations	
Additionally, in case of a slump	Not applicable
sale, indicative disclosures	
provided for amalgamation/	
merger, shall be disclosed by the	
listed entity with respect to such	
slump sale.	
•	